St. Jude Medical Begins Landmark Clinical Study To Evaluate Effectiveness Of Ablation Procedures For Treatment Of Ventricular Tachycardia
ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the first patient enrollment in the STAR-VT (Substrate Targeted Ablation using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia) clinical trial, a prospective, multi-center, randomized study evaluating the safety and efficacy of the FlexAbility™ ablation catheter when used in ventricular tachycardia (VT) ablation procedures. The STAR-VT trial will assess whether combining targeted ablation with either an implantable cardiac defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) can reduce the incidence and economic burden of recurring ventricular arrhythmias better than treatment with either an ICD or CRT-D and medication alone.
“For many years, implantable cardioverter defibrillators have been one of the primary treatment options for patients with ventricular arrhythmias,” said Dr. Andrea Natale, executive medical director at the Texas Cardiac Arrhythmia Institute. “While these are life-saving therapies, patient risks associated with the recurrence of ventricular tachycardia, such as frequent shocks from an implantable defibrillator, still exist. This study is important because it may provide further evidence that ablation therapies are more effective than medication in suppressing recurring ventricular tachycardia and, with it, the freedom from shocks and repeat cardiovascular hospitalizations for my patients.”
Help employers find you! Check out all the jobs and post your resume.
“For many years, implantable cardioverter defibrillators have been one of the primary treatment options for patients with ventricular arrhythmias,” said Dr. Andrea Natale, executive medical director at the Texas Cardiac Arrhythmia Institute. “While these are life-saving therapies, patient risks associated with the recurrence of ventricular tachycardia, such as frequent shocks from an implantable defibrillator, still exist. This study is important because it may provide further evidence that ablation therapies are more effective than medication in suppressing recurring ventricular tachycardia and, with it, the freedom from shocks and repeat cardiovascular hospitalizations for my patients.”
Help employers find you! Check out all the jobs and post your resume.